30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

2Q14 Revenue: DePuy Synthes/Johnson & Johnson

US $2,469MM, +3% (U.S. $1,294MM, +2%, ex-U.S. $1,175MM, +5%)

  • Hips +5%
  • Knees +1% (U.S. flat, ex-U.S. +4%)
  • Trauma +7% (ex-U.S. +11%)
  • Spine +1% (U.S. -2%, ex-U.S. +4%)


  • Growth drivers: Successful tender offer from comprehensive trauma portfolio in Middle East, strong hip volume growth (notably primary stem platform sales), Attune knee
  • Growth partially offset by price pressure, softness in U.S. market
  • Commenced U.S. launch of Corail revision hip, and U.S. and EU launch of Global Unite Anatomic Shoulder
  • U.S. pricing update: Hips -4%, positive mix of +0.5%, net -3.5%; knees -2.6%, positive mix +1.5%, net -1.1%; trauma price + mix +2.2%; spine -5% with positive mix 1.4%, net -3.5%
  • Notes a cyclical trend in particular knee procedures, perhaps a shift toward the “back end” of the year
  • Planning 3Q launch of VA-LCP Midfoot/Hindfoot low profile plating system in U.S. and EU